Golgi protein 73(GP73), a useful serum marker in liver diseases

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 8, 2011, Pages 1311-1316

  Liu, Xiangyi ^a   Wan, Xiaohua ^a   Li, Zhongwu ^b   Lin, Changqing ^c   Zhan, Yutao ^a   Lu, Xinxin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c Hotgen Biotechnology Co Ltd   (China)

Author keywords

chronic hepatitis B (CHB); Golgi protein 73 (GP73); hepatocellular carcinoma (HCC); liver fibrosis

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CELL PROTEIN; COLLAGEN TYPE 4; GOLGI PROTEIN 73; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID; LAMININ; PLASMA PROTEIN; PROCOLLAGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOLGI COMPLEX; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIBODIES; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED;

HEPATITIS B VIRUS;

EID: 80051747370     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.640     Document Type: Article

References (36)

1. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000;249:53-65. (Pubitemid 30300752)
2. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and non-viral liver disease. Hepatology 2002;35:1431-40. (Pubitemid 34966897)
3. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Gräff A, Gusmirovic I, Solomon H, et al. Disease-and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 2004; 99:1087-95. (Pubitemid 38917813)
4. Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010;59:1687-93.
5. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010;45:1272-82.
6. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:1914-21.
7. Kim KH, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. Molecules 2010;15: 5878-908.
8. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005;24:5858-67. (Pubitemid 43080077)
9. Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol 2008;1:61-75.
10. Hollinger FB, Lau DT. Hepatitis B: The pathway to recovery through treatment. Gastroenterol Clin North Am 2006;35: 425-61.
11. Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, et al. Liver fibrosis: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009;3:323-33.
12. Hepatobiliary Surgery Group, Chinese Society of Surgery, Chinese Medical Association. 2004 guidelines for surgical treatment of primary hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2005;13:329-30.
13. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2005;13:881-91.
14. Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yüksel O, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion 2011;83:83-8.
15. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005;102:779-84. (Pubitemid 40282742)
16. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010;55:2744-55.
17. Bayram A, Erkilic S, Ozkur A, Bayram M, Sari I. Quantification of intrahepatic total hepatitis B virus DNA in chronic hepatitis B patients and its relationship with liver histology. J Clin Pathol 2008;61:338-42. (Pubitemid 351354241)
18. Yuen MF, Ng IO, Fan ST, Yuan HJ, Wong DK, Yuen JC, et al. Significance of HBV DNA levels in liver histology of HBeAg and anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol 2004;99:2032-7. (Pubitemid 39421251)
19. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 -summary of a workshop. Gastroenterology 2001; 120:1828-53.
20. Zhu R, Huang H, Zhang H, Wang Z, Hu X, Zhai W, et al. Prognostic analysis in chronic hepatitis B patients: A retrospective study of 216 cases about Scheuer scores, in situ expression of viral antigens and tissue hepatitis B virus DNA levels. Liver Int 2006;26:82-9.
21. Lee CZ, Huang GT, Yang PM, Sheu JC, Lai MY, Chen DS. Correlation of HBV DNA levels in serum and liver of chronic hepatitis B patients with cirrhosis. Liver 2002;22:130-5. (Pubitemid 34591254)
22. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000;7:258-67.
23. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B? Liver 1997;17:83-7. (Pubitemid 27179981)
24. Vizzutti F, Arena U, Rega L, Pinzani M. Non-invasive diagnosis of portal hypertension in cirrhotic patients. Gastroenterol Clin Biol 2008;32:80-7.
25. Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D, Fard MK, et al. Serum hyaluronic acid and laminin as biomarkers in liver fibrosis. J Gastrointestin Liver Dis 2010;19:169-74.
26. Santos VN, Leite-Mór MM, Kondo M, Martins JR, Nader H, Lanzoni VP, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005;38:747-53. (Pubitemid 40867514)
27. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006;26: 864-71. (Pubitemid 44165255)
28. Xie SB, Yao JL, Zheng RQ, Peng XM, Gao ZL. Serum hyaluronic acid, procollagen type III and IV in histological diagnosis of liver fibrosis. Hepatobiliary Pancreat Dis Int 2003;2: 69-72.
29. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24. (Pubitemid 34183954)
30. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
31. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepat 2009;16:453-63.
32. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
33. Benowitz S. Liver cancer biomarkers struggling to succeed. J Natl Cancer Inst 2007;99:590-1.
34. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009;3:353-67.
35. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
36. Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, et al. Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 2010 Dec 7. wEpub ahead of printx PMID: 21140449 DOI: 10.1002/ijc.25838.